
### [NCIT:C34448](http://purl.obolibrary.org/obo/NCIT_C34448)
**Label:** Carcinosarcoma

**Subclasses:** [NCIT:C113239](http://purl.obolibrary.org/obo/NCIT_C113239) (Uterine Carcinosarcoma, Heterologous Type), [NCIT:C113238](http://purl.obolibrary.org/obo/NCIT_C113238) (Uterine Carcinosarcoma, Homologous Type), [NCIT:C8975](http://purl.obolibrary.org/obo/NCIT_C8975) (Malignant Mixed Mesodermal (Mullerian) Tumor), [NCIT:C45543](http://purl.obolibrary.org/obo/NCIT_C45543) (Lung Carcinosarcoma), [NCIT:C42700](http://purl.obolibrary.org/obo/NCIT_C42700) (Uterine Carcinosarcoma), [NCIT:C40124](http://purl.obolibrary.org/obo/NCIT_C40124) (Fallopian Tube Carcinosarcoma), [NCIT:C96939](http://purl.obolibrary.org/obo/NCIT_C96939) (Extrahepatic Bile Duct Carcinosarcoma), [NCIT:C36097](http://purl.obolibrary.org/obo/NCIT_C36097) (Cervical Carcinosarcoma), [NCIT:C9192](http://purl.obolibrary.org/obo/NCIT_C9192) (Ovarian Carcinosarcoma), [NCIT:C9180](http://purl.obolibrary.org/obo/NCIT_C9180) (Uterine Corpus Carcinosarcoma), [NCIT:C35831](http://purl.obolibrary.org/obo/NCIT_C35831) (Carcinosarcoma of the Salivary Gland), [NCIT:C96888](http://purl.obolibrary.org/obo/NCIT_C96888) (Gallbladder Carcinosarcoma), [NCIT:C96848](http://purl.obolibrary.org/obo/NCIT_C96848) (Liver Carcinosarcoma), [NCIT:C35832](http://purl.obolibrary.org/obo/NCIT_C35832) (Parotid Gland Carcinosarcoma), 

**Class expressions from DL-Learner:**

- [NCIT:C54727](http://purl.obolibrary.org/obo/NCIT_C54727) (Sarcomatous Component Present) 55.00%
- Thing 52.53%
- [NCIT:C61466](http://purl.obolibrary.org/obo/NCIT_C61466) (Malignant Component Present) 45.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39130](http://purl.obolibrary.org/obo/NCIT_C39130) (Insulin Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39128](http://purl.obolibrary.org/obo/NCIT_C39128) (IL7 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39124](http://purl.obolibrary.org/obo/NCIT_C39124) (IL3 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39123](http://purl.obolibrary.org/obo/NCIT_C39123) (IL2RB Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39121](http://purl.obolibrary.org/obo/NCIT_C39121) (IL22 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39117](http://purl.obolibrary.org/obo/NCIT_C39117) (IL12 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39114](http://purl.obolibrary.org/obo/NCIT_C39114) (IGF-1 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39112](http://purl.obolibrary.org/obo/NCIT_C39112) (IFN Gamma Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39103](http://purl.obolibrary.org/obo/NCIT_C39103) (ERBB2 Signaling Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39102](http://purl.obolibrary.org/obo/NCIT_C39102) (Skeletal Myogenesis Pathway))) 40.36%
- [NCIT:C54172](http://purl.obolibrary.org/obo/NCIT_C54172) (Carcinomatous Component Present) and (not ([NCIT:C39101](http://purl.obolibrary.org/obo/NCIT_C39101) (Human Cytomegalovirus Infection Pathway))) 40.36%


